Derivatives of Amodiaquine as Potent Human Cholinesterases Inhibitors: Implication for Treatment of Alzheimer’s Disease
2024

Amodiaquine Derivatives as Potential Alzheimer's Disease Treatments

Sample size: 14 publication 10 minutes Evidence: high

Author Information

Author(s): Matošević Ana, Opsenica Dejan M., Bartolić Marija, Maraković Nikola, Stoilković Andriana, Komatović Katarina, Zandona Antonio, Žunec Suzana, Bosak Anita

Primary Institution: Institute for Medical Research and Occupational Health, Zagreb, Croatia

Hypothesis

Can amodiaquine derivatives effectively inhibit human cholinesterases and serve as potential treatments for Alzheimer's disease?

Conclusion

The study identified several amodiaquine derivatives as potent inhibitors of cholinesterases, with potential applications in treating Alzheimer's disease.

Supporting Evidence

  • All synthesized derivatives were potent inhibitors of both cholinesterases.
  • Compound 5 was identified as the most potent AChE inhibitor.
  • Most compounds were able to cross the blood-brain barrier.
  • Compounds exhibited antioxidant properties comparable to standard antioxidants.
  • All compounds were non-toxic towards tested cell lines at effective concentrations.

Takeaway

Scientists made new versions of a medicine called amodiaquine to see if they could help treat Alzheimer's disease by stopping certain brain chemicals from breaking down too quickly.

Methodology

The study synthesized 14 amodiaquine derivatives and tested their ability to inhibit acetylcholinesterase and butyrylcholinesterase, along with assessing their antioxidant and metal chelation properties.

Limitations

The study primarily focused on in vitro results, and further in vivo studies are needed to confirm the efficacy and safety of the compounds.

Digital Object Identifier (DOI)

10.3390/molecules29225357

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication